MIAMI, July 25, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. ATXI (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (“FDA”) on key…Read More
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol Fortress Biotech NASDAQFBIO Avenue Therapeutics NASDAQATXI
